HRT Financial’s Sarepta Therapeutics SRPT Stock Holding History

HRT Financial’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-294,112	Closed	-$5.69M	–	4677
2025 Q4	$6.33M	Buy	294,112 +112,257	+62%	+$2.37M	0.02%	674
2025 Q3	$3.5M	Buy	181,855 +70,197	+63%	+$1.25M	0.01%	843
2025 Q2	$1.91M	Buy	111,658 +76,514	+218%	+$3.26M	0.01%	944
2025 Q1	$2.24M	Buy	+35,144	New	+$3.7M	0.01%	763
2024 Q2	–	Sell	-33,738	Closed	-$4.37M	–	3053
2024 Q1	$4.37M	Buy	33,738 +26,126	+343%	+$3.2M	0.03%	300
2023 Q4	$734K	Buy	+7,612	New	+$730K	0.01%	1150
2023 Q2	–	Sell	-76,799	Closed	-$10.6M	–	3239
2023 Q1	$10.6M	Buy	76,799 +34,456	+81%	+$4.47M	0.13%	128
2022 Q4	$5.49M	Buy	+42,343	New	+$4.91M	0.08%	241
2022 Q3	–	Sell	-57,771	Closed	-$4.33M	–	3475
2022 Q2	$4.33M	Buy	+57,771	New	+$4.25M	0.05%	296
2022 Q1	–	Sell	-16,124	Closed	-$1.45M	–	3821
2021 Q4	$1.45M	Buy	+16,124	New	+$1.38M	0.01%	862
2021 Q1	–	Sell	-3,083	Closed	-$525K	–	3121
2020 Q4	$525K	Buy	+3,083	New	+$457K	0.01%	999

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

HRT Financial's SRPT Position: Q1 2026 in Review

HRT Financial sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 294,112 shares — an estimated $5.69M sold.

HRT Financial first reported a position in SRPT in Q4 2020 and held it in 11 quarters. The position peaked at $10.6M in Q1 2023. 344 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

HRT Financial reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 294,112 Sarepta Therapeutics shares in Q1 2026, an estimated $5.69M.
HRT Financial first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 11 quarters.
HRT Financial's Sarepta Therapeutics position peaked at $10.6M in Q1 2023.
344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.